[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moyamoya-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moyamoya-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,40,70,98,141,170,195,216,237,259,666,688,711,731,753,778,805,828,859],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100621982","remimazolam-consumption-tci-vs-manual-infusion-100621982",false,"NCT07377695","Remimazolam Consumption: TCI vs. Manual Infusion","Comparison of Remimazolam Consumption According to Administration Method in Patients Undergoing Cerebrovascular Bypass Surgery: A Prospective Randomized Trial","Inclusion Criteria:\n\n* Patients scheduled to undergo cerebrovascular bypass surgery under general anesthesia.\n* American Society of Anesthesiologists (ASA) Physical Status 1, 2, or 3\n* Adults aged 19 years or older\n* Patients who have provided prior written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients who do not consent to participate in the research\n* Patients classified as ASA Physical Status 4\n* Patients with a BMI ≤18.5 kg\u002Fm2 or 35.0 ≥ kg\u002Fm2\n* History of allergy to benzodiazepine-class medications\n* Patients with acute narrow-angle glaucoma\n* Patients in a state of shock or coma\n* Acute alcohol intoxication with suppressed vital signs , or patients with alcohol or drug dependency\n* Presence of Sleep Apnea Syndrome or severe\u002Facute respiratory failure\n* Patients with lactose intolerance or hypersensitivity to Dextran 40","ALL","19 Years",{"count":19,"type":20},58,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this prospective randomized controlled trial is to compare the total consumption of remimazolam between two different administration methods-Target-Controlled Infusion (TCI) and manual infusion-in patients undergoing cerebrovascular bypass surgery.",[26],"Moyamoya Disease","RECRUITING","2026-04-22",{"date":30,"type":31},"2026-04-23","ACTUAL",{"date":33,"type":31},"2026-02-04",{"date":35,"type":20},"2030-12-31",{"name":37,"class":38},"Seoul National University Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100632720","family-based-moyamoya-susceptibility-and-early-detection-100632720","NCT07517354","Family-Based Moyamoya Susceptibility and Early Detection","The FAME Study: A Family-Based Cohort Study on Moyamoya Disease Susceptibility and Early Screening","FAMES","Inclusion Criteria:\n\n* Participants must belong to 1 of the following 3 cohorts:\n\nMoyamoya disease cohort: diagnosed with primary moyamoya disease according to standard diagnostic criteria, with progressive stenosis or occlusion at the terminal internal carotid arteries and\u002For their major branches and typical collateral vessels on DSA, CTA, or MRA; newly diagnosed and previously diagnosed cases are both eligible; no age or sex restriction.\n\nFirst-degree relative cohort: first-degree blood relatives of patients with moyamoya disease, including parents, children, and siblings; no age or sex restriction; no clinical diagnosis of moyamoya disease and no history of stroke or other cerebrovascular events at enrollment; baseline MRI does not show definite moyamoya disease, although mild changes are allowed.\n\nHealthy control cohort: no family history of moyamoya disease; no personal history of cerebrovascular disease; no major abnormalities on physical examination or baseline screening; age and sex distribution matched as closely as possible to the moyamoya disease cohort.\n\nExclusion Criteria:\n\n* Major systemic or central nervous system diseases that may interfere with study results or substantially affect survival or adherence, such as advanced malignant tumors, active tuberculosis or other serious infections, active systemic lupus erythematosus, or severe hepatic or renal dysfunction.\n\nAtypical cerebrovascular lesions on baseline imaging, such as widespread atherosclerotic stenosis or congenital vascular malformations.\n\nInability to complete examinations or follow-up, including MRI contraindications such as non-compatible metal implants or severe claustrophobia, expected difficulty completing follow-up because of long-term relocation, poor communication access, poor adherence, or other situations judged by the investigators to make participation inappropriate.\n\nPregnant women.",true,{"count":50,"type":20},700,"3 Years","OBSERVATIONAL","This single-center, prospective, family-based observational cohort study aims to investigate susceptibility to moyamoya disease (MMD) and to develop strategies for early screening in individuals at increased familial risk. The study will enroll three groups: patients with MMD, their first-degree relatives, and healthy controls without a family history of MMD.\n\nThe rationale for this study is that MMD has an important genetic component, but genetic susceptibility alone does not fully explain disease onset. Current diagnosis often relies on angiographic evaluation after symptoms have already appeared. This study seeks to identify earlier, less invasive biological and imaging markers that may help detect individuals at high risk before overt clinical disease develops.\n\nAt baseline, participants will undergo collection of demographic and clinical data, vascular risk factors, neurological assessments, routine laboratory testing, and 5T high-resolution magnetic resonance imaging. Biospecimens including blood, urine, stool, saliva, and nasal swabs will be collected for multi-omics and biomarker analyses; surgically obtained tissue specimens may also be collected from patients undergoing clinically indicated surgery.\n\nParticipants in the patient and first-degree relative groups will be followed annually for 3 years, primarily by telephone or online questionnaire, with optional repeat 5T MRI during follow-up. The primary objective is to identify baseline biological and imaging features associated with incident MMD in first-degree relatives and to establish an interpretable early-screening framework for high-risk populations.",[26],[26,56,57,58,59,60],"Early Screening","Family-Based Cohort","Biomarkers","High-Resolution MRI","Multi-omics","2026-04-01",{"date":63,"type":31},"2026-04-08",{"date":65,"type":31},"2024-11-12",{"date":67,"type":20},"2030-11-30",{"name":69,"class":38},"Beijing Tiantan Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":39},"100570965","application-of-digital-twins-technology-in-patients-who-had-a-stroke-with-moyamoya-disease-and-with-cerebral-amyloid-angiopathy-caa-during-the-secondary-prevention-phase-a-proof-of-concept-using-a-randomized-control-trial-clinical-study-6-stratif-ai-project-100570965","NCT06714097","Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)","SMART","Inclusion Criteria:\n\n* People aged ≥ 18\n* Clinical and neuroradiological diagnosis of stroke (TAC or MR); diagnosis of CAA based on Boston 2.0 criteria; diagnosis of Moyamoya disease based on diagnostic criteria 2021.\n* MOCA total score ≥ 23\n* modified Rankin Scale (mRS) ≤ 2\n* First-time patients at the Besta Institute\n* Ability to sign informed consent\n* Possibility of performing a brain MRI\n\nExclusion Criteria:\n\n* Patients with transient neurological deficits that resolve within an hour and normal brain imaging\n* Patient under legal protection or deprived of liberty by judicial or administrative decision\n* Patient whose follow-up will be impossible\n* Contraindication to magnetic resonance imaging and\u002For Digital subtraction angiography (DSA)\n* Pregnant patients\n* Known or suspected drug or alcohol abuse","18 Years",{"count":79,"type":20},20,[23],"The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid angiopathy, including adults of both sexes.\n\nThe main questions it aims to answer is: how is the patients' experience regarding the use of the STRATIF-AI platform? Researchers will compare Arm 1, who use the STRATIF-AI app in addition to standard secondary prevention, against Arm 2, who receive standard secondary prevention only, to collect feedback regarding the platform usability.\n\nParticipants in the Arm 1 will:\n\n* Complete cognitive and psychological assessments at the time of the first visit and after six months\n* Follow the indications received from the clinician for standard secondary prevention\n* Use the STRATIF-AI app daily for health management\n* Optionally, purchase wearable devices that connect to the app.\n* Participate in interviews at the six-month mark to share their experiences with the app.\n\nPatients in the Arm 2 will:\n\n* Complete cognitive and psychological assessments at the time of the first visit and after six months\n* Follow the indications received from the clinician for standard secondary prevention",[83,26,84],"Stroke","Cerebral Amyloid Angiopathy",[86,87,88,26,84],"stroke","secondary prevention","digital twin","2026-03-25",{"date":91,"type":31},"2026-03-30",{"date":93,"type":20},"2026-04",{"date":95,"type":20},"2027-04",{"name":97,"class":38},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":108,"conditions":109,"keywords":132,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},"100571728","neurosurgical-outcome-network-100571728","NCT06724029","Neurosurgical Outcome Network","Neurosurgical Outcome Network Per la Predizione Dell'Outcome in Neurochirurgia","NEON","Inclusion Criteria:\n\n* Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region)\n* Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial\u002Fparasellar development.\n* Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas)\n* Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute\u002Fsubacute\u002Fchronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery.\n* Spinal pathology: degenerative cervical (anterior\u002Fposterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology.\n* Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain\u002Falgia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus.\n* Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section)\n* Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus.\n* For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology\n\nExclusion Criteria:\n\n* For cognitive and psychological assessment: patients with psychiatric diseases in history and\u002For taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.",{"count":107,"type":20},4500,"The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to assess outcomes and their predictors using measures agreed upon by the participating centers. Standardizing the evaluation of outcomes and predictors improves the quality of research, allows for data comparison, and facilitates a \"common language\" in routine clinical practice. Most importantly, it influences therapeutic decisions in various neurosurgical conditions. Clinically, the identified predictors can also be used during preoperative assessments to provide more precise guidance to patients undergoing surgery.",[110,111,112,113,26,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131],"Aneurysms","Arteriovenous Malformations","Cavernomas","Skull Base Tumors","Dural Fistulas","Subdural Hematoma","Extradural Hematoma","Subarachnoid Hemorrhage","Hydrocephalus","Parkinson&Amp;#39;s Disease","Spasticity","Trigeminal Neuralgia","Craniofacial Pain","Neuropathic Pain","Tremor","Dystonias","Obsessive-compulsive Disorder","Drug-resistant Epilepsy","Depression","Normal Pressure Hydrocephalus","Tumors of Peripheral Nerves","Chiari Malformation Type 1",[133],"Neurosurgery Outcome Artificial Intelligence predictors",{"date":91,"type":31},{"date":136,"type":31},"2022-12-05",{"date":138,"type":20},"2027-06",{"name":97,"class":38},27,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":48,"sex":16,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":39},"100604085","cognitive-motor-incorporated-training-and-its-relations-in-cerebrovascular-diseases-with-cognitive-and-motor-impairments-100604085","NCT07144930","Cognitive-Motor Incorporated Training and Its Relations in Cerebrovascular Diseases With Cognitive and Motor Impairments","Impact of Cognitive-Motor Incorporated Training and Brain Activation Patterns in Cerebrovascular Diseases With Cognitive and Motor Impairments: Post Stroke Cognitive Impairment and Moyamoya Disease","Part 1:\n\nInclusion Criteria:\n\n* For aged-matched healthy controls:\n\n  1. being 20 years of age or older\n  2. the ability to stand for more than 30 seconds\n  3. a MoCA score of higher than 26.\n* For PSCI participants:\n\n  1. Diagnosis of stroke confirmed by brain CT or MRI, with symptom onset more than 7 days prior (subacute or chronic phase)\n  2. Being 20 years of age or older\n  3. The ability to stand for more than 30 seconds\n  4. a MoCA score of less than 26\n* For the MMD group:\n\n  1. a confirmed diagnosis of Moyamoya disease or Moyamoya syndrome through CT scan or angiography\n  2. If stroke occurred, being in the subacute phase (one week post-stroke)\n  3. being 20 years of age or older\n  4. the ability to stand for more than 30 seconds\n  5. a MoCA score of less than 26\n\nExclusion Criteria:\n\n1. unstable or uncontrolled vital signs, including a resting heart rate \\>100 or \\\u003C40 BPM, a respiratory rate \\>20 or \\\u003C12 breaths per minute, an SpO2 \\\u003C 95%, a central arterial pressure (CAP) \\\u003C80 mmHg, and individuals requiring ICP monitoring will also be excluded\n2. requiring invasive mechanical ventilation or being deemed unsuitable by the attending physician due to unstable medical conditions\n3. the presence of other neurological disorders or unstable vital signs may interfere with the experiment\n4. currently hospitalized in the intensive care unit (ICU)\n5. Severe visual or hearing impairments, or communication and comprehension difficulties that interfere with study participation\n\nPart 2:\n\nInclusion Criteria:\n\n1. Diagnosis of stroke confirmed by brain CT or MRI, with symptom onset more than 7 days prior (subacute or chronic phase)\n2. Being 20 years of age or older\n3. The ability to stand for more than 30 seconds\n4. a MoCA score of less than 26\n\nExclusion Criteria:\n\n1. unstable or uncontrolled vital signs, including a resting heart rate \\>100 or \\\u003C40 BPM, a respiratory rate \\>20 or \\\u003C12 breaths per minute, an SpO2 \\\u003C 95%, a central arterial pressure (CAP) \\\u003C80 mmHg, and individuals requiring ICP monitoring will also be excluded\n2. requiring invasive mechanical ventilation or being deemed unsuitable by the attending physician due to unstable medical conditions\n3. the presence of other neurological disorders or unstable vital signs may interfere with the experiment\n4. currently hospitalized in the intensive care unit (ICU)\n5. Severe visual or hearing impairments, or communication and comprehension difficulties that interfere with study participation\n\nPart 3:\n\nInclusion Criteria:\n\n1. Moyamoya disease\u002Fsyndrome confirmed through CT scan or angiography\n2. being in the subacute phase, defined as one week after stroke onset\n3. being 20 years of age or older\n4. the ability to stand for more than 30 seconds\n5. a Montreal Cognitive Assessment (MoCA) score of less than 26.\n\nExclusion Criteria:\n\n1. unstable or uncontrolled vital signs, including a resting heart rate \\>100 or \\\u003C40 BPM, a respiratory rate \\>20 or \\\u003C12 breaths per minute, an SpO2 \\\u003C 95%, a central arterial pressure (CAP) \\\u003C80 mmHg, and individuals requiring ICP monitoring will also be excluded\n2. requiring invasive mechanical ventilation or being deemed unsuitable by the attending physician due to unstable medical conditions\n3. the presence of other neurological disorders or unstable vital signs that could interfere with the experiment\n4. currently hospitalized in the intensive care unit (ICU)\n5. Severe visual or hearing impairments, or communication and comprehension difficulties that interfere with study participation.","20 Years","100 Years",{"count":151,"type":20},210,[23],"The following three-part proposal will explore the impact of applying motor-cognitive incorporated training (MCIT) in individuals with post-stroke cognitive impairment (PSCI) or Moyamoya disease (MMD), and examine the relationship between cognitive and motor impairments and brain activation patterns in these populations.\n\nPart I is a cross-sectional study designed to characterize cognitive and motor performance and their relationship with brain activation patterns in individuals with post-stroke cognitive impairment (PSCI) or Moyamoya disease (MMD), compared to age-matched healthy controls. Thirty participants will be screened for eligibility and recruited for each group (90 participants total). After collecting basic data, all participants will undergo cognitive and motor function tests. Cognitive function tests include tests of global cognition, and executive function. Motor function tests include tests of sensorimotor function, single and dual task standing, muscle strength, and ambulation ability. Functional near-infrared spectroscopy (fNIRS) will be used to evaluate the brain activation during the cognitive tests, and single and dual task standing. Results from all tests will be used to determine the motor, cognitive, and other functional performance, and will be used in the design of the training program in Part II and III.\n\nPart II and III are single-blinded randomized controlled trials that will explore the short and long-term effects of a motor-cognitive incorporated training (MCIT) on motor, and cognitive function in individuals with post-stroke cognitive impairment (PSCI) or Moyamoya disease (MMD). 60 individuals with PSCI (Part II), and 60 individuals with MMD (Part III) will be recruited. After screening for eligibility and collection of demographic data, participants will undergo a pretest assessment. In addition to the motor and cognitive tests used in Part I, stroke location, and time of onset will also be collected for each participant. Brain activation will be assessed during the cognitive tests, single and dual task standing assessments using fNIRS. Participants will be randomly allocated to one of the two groups (MCIT group and active control group) (n=30 in each group) via a sealed envelope selected by a blinded assistant. The training protocol is 30 minutes per session, 3 sessions per week for a total of 4 weeks. The control group will receive motor training only, including upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks. The MCIT group will engage in the program combines motor and cognitive training that starts with attention and short-term memory tasks, advancing to working memory and inhibitory control with increasing difficulty. A post-test will be conducted after the 4-week intervention, followed by follow-up assessments at 1, 3, and 12 months for individuals with PSCI or MMD in both the control group and the MCIT group. At the 3-month follow-up, participants who are unable to attend in person will be contacted by telephone. At the 12-month follow-up, all participants will receive a telephone interview focused on return-to-work status.",[26,155,83],"Healthy",[83,157,158,159,160],"Motor-cognitive incorporated training","Cognitive function","Motor function","Post-stroke cognitive impairment","2026-01-28",{"date":163,"type":31},"2026-01-30",{"date":165,"type":31},"2025-06-23",{"date":167,"type":20},"2028-08-31",{"name":169,"class":38},"National Taiwan University Hospital",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":39},"100614939","phase-1-chinese-herbal-therapy-qiqi-shengmai-formula-for-moyamoya-vasculopathy-the-chimes-trial-100614939","NCT07286110","Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial","Effect of Chinese Herbal Intervention (Qiqi Shengmai Formula) for Moyamoya Vasculopathy in Cerebral Hemodynamics (CHIMES ): a Single-center, Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. Imaging findings meeting the Western medical diagnostic criteria for moyamoya vasculopathy\n2. Age between 18 and 80 years\n3. The patient and family members are fully informed and voluntarily consent to participation, with the informed consent process conducted in accordance with GCP requirements\n4. Willingness to receive Traditional Chinese Medicine treatment\n5. Traditional Chinese Medicine syndrome differentiation consistent with liver-yang hyperactivity\n\nExclusion Criteria:\n\n1. Acute cerebrovascular events within the preceding 6 weeks\n2. Known allergy to contrast agents or to the investigational medication\n3. Presence of severe primary diseases involving the cardiac, pulmonary, hepatic, renal, endocrine, or hematopoietic systems\n4. Pregnant or breastfeeding women\n5. Patients scheduled to undergo cerebral revascularization surgery\n6. Participation in other ongoing clinical trial","80 Years",{"count":179,"type":20},66,[181],"PHASE1","Patients diagnosed with moyamoya vasculopathy by imaging and classified as having the Traditional Chinese Medicine (TCM) syndrome of liver-yang hyperactivity will be enrolled. On the basis of standardized Western medical management, participants will receive the standardized TCM herbal formula \"Qiqi Shengmai Formula\" (comprising Astragali Radix, Rehmanniae Radix Praeparata, Schisandrae Fructus, Bupleuri Radix, Paeoniae Radix Alba, and Notoginseng Radix). Structured follow-up will be conducted. By comparing endpoint indicators across different treatment regimens, the study aims to evaluate the efficacy of integrated TCM-Western medicine therapy for moyamoya vasculopathy and to generate evidence-based support for an integrated diagnostic and therapeutic model.",[26,184],"Moyamoya Syndrome","NOT_YET_RECRUITING","2025-12-16",{"date":188,"type":31},"2025-12-22",{"date":190,"type":20},"2025-12-30",{"date":192,"type":20},"2026-12-30",{"name":194,"class":38},"Fudan University",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":202,"maxAge":77,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":39},"100616387","cardiac-index-guided-intraoperative-hemodynamic-management-in-pediatric-moyamoya-surgery-100616387","NCT07304947","Cardiac Index-Guided Intraoperative Hemodynamic Management in Pediatric Moyamoya Surgery","Personalized Cardiac Index-Guided Intraoperative Hemodynamic Management to Improve Postoperative Outcomes in Pediatric Patients With Moyamoya Disease: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pediatric patients \\\u003C18 years undergoing EDAS for Moyamoya disease under general anesthesia\n\nExclusion Criteria:\n\n* ASA physical status 4-5\n* Emergency surgery\n* Known cardiovascular disease\n* Any condition judged inappropriate by investigators","1 Month",{"count":204,"type":20},94,[23],"This prospective randomized controlled trial evaluates whether individualized cardiac index-guided intraoperative hemodynamic management reduces postoperative transient ischemic episodes in pediatric patients undergoing encephaloduroarteriosynangiosis (EDAS) for Moyamoya disease. Patients are randomized 1:1 to goal-directed fluid therapy based on baseline cardiac index versus standard arterial pressure-based management. The primary outcome is the incidence of transient ischemic episodes during hospitalization.",[26],"2025-12-11",{"date":210,"type":31},"2025-12-26",{"date":212,"type":20},"2025-12-02",{"date":214,"type":20},"2029-01-31",{"name":37,"class":38},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":39},"100603762","the-symani-restore-study-100603762","NCT07140731","The Symani Restore Study","An Early Feasibility Study for the Symani Surgical System","Inclusion Criteria:\n\n1. Patients aged \\>18.\n2. Moyamoya disease with minor to moderate symptoms requiring neurosurgical treatment.\n3. Patients agree to have the surgery and the anesthesia.\n4. Patients who voluntarily decide to participate in this study with the surgery performed with the aid of Symani and agree to sign the Informed Consent Form.\n\n   \\-\n\nExclusion Criteria:\n\n1. Patients who have bleeding or coagulation disorders in the past or present.\n2. Any criteria that preclude prolonged anesthesia.\n3. Hemodynamically unstable neurological exam.\n4. Pressure dependent neurologic status.",{"count":224,"type":20},15,[23],"A research study for a neurosurgical procedure in adult patients with Moyamoya disease",[26],"2025-10-14",{"date":230,"type":31},"2025-10-16",{"date":232,"type":31},"2025-09-20",{"date":234,"type":20},"2027-09-01",{"name":236,"class":38},"Jacobs institute",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":21,"phases":247,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":39},"100597970","phase-1-treatment-of-moyamoya-disease-with-ipsc-derived-exosomes-100597970","NCT07065409","Treatment of Moyamoya Disease With iPSC-derived Exosomes","Phase I Clinical Trial of Induced Pluripotent Stem Cell-derived Extracellular Vesicles Combined With Temporal Muscle Flap Application in Promoting Intracranial and Extracranial Blood Flow Reconstruction in Patients With Moyamoya Disease","Inclusion criteria:\n\n1. Diagnosed adult patients with MMD aged 18-75 years (inclusive), with bilateral terminal occlusion of the internal carotid arteries (ICA) and stenosis or occlusion of the anterior cerebral artery (ACA) and middle cerebral artery (MCA) at the origin, accompanied by the formation of abnormal vascular networks at the base of the skull, as indicated by head DSA or MRA. Unilateral or bilateral lesions are acceptable. Suzuki score ≥ 3.\n2. Relevant bone marrow, liver, kidney, and heart function indicators meet the following standards (based on the normal values of the clinical trial center): absolute neutrophil count (ANC) ≥ 1.5×109\u002FL, platelets ≥ 100×109\u002FL, total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), ALT, AST, or ALP ≤ 3 times ULN; serum creatinine ≤ 1.5 times ULN, international normalized ratio (INR) ≤ 1.5 times ULN, APTT ≤ 1.5 times ULN.\n3. Patients have undergone temporal muscle patch surgery and have not achieved satisfactory improvement in symptoms.\n4. Patients have been followed up for ≥ 3 months since the surgery.\n5. Vascular DSA performed 3 months after the surgery indicates poor blood flow reconstruction.\n6. CTP or ASL performed 3 months after the surgery shows ischemia.\n7. Patients still have clinical manifestations of cerebral ischemia or cerebral infarction due to MMD 3 months after the surgery.\n8. Patients or their legal representatives have given informed consent and signed the informed consent form.\n\nExclusion criteria:\n\n1. Patients with severe liver or kidney dysfunction or other complications;\n2. Patients with a history of mental disorders or mental diseases;\n3. Patients with coagulation disorders;\n4. Patients with extensive cerebral infarction or in a coma;\n5. Patients who only undergo direct bypass surgery;\n6. Patients who have not signed the surgical consent form;\n7. Patients with allergic constitutions or a clear history of allergies;\n8. Pregnant women, lactating women, and patients with plans to conceive during the trial period;\n9. Patients who have participated in other clinical trials in the past three months;\n10. Patients deemed unsuitable for the trial by the researcher.","75 Years",{"count":246,"type":20},9,[181],"Moyamoya disease is a cerebrovascular disease clinically characterized by chronic progressive stenosis or occlusion at the ends of bilateral internal carotid arteries and the origin of anterior cerebral arteries and middle cerebral arteries, followed by the formation of abnormal vascular networks at the base of the skull. Clinically, patients with Moyamoya disease mainly present with ischemic or hemorrhagic stroke, and there are two peaks of incidence in children aged 3-5 and middle-aged people aged 40-50. Moreover, as the pathogenesis and treatment evaluation of Moyamoya disease are still in the research trough at present, new discoveries are prone to occur and thus attract a great deal of attention. It not only has a beneficial promoting effect on the treatment and diagnosis of patients, but also makes it easier for research topics to be reported in top journals.\n\nThis study intends to combine iPSC-EVs local skin transplantation with temporal muscle application to promote muscle angiogenesis and the establishment of extracranial and intracranial collateral circulation after temporal muscle application. The above-mentioned design features high efficiency, safety and convenience, and is an innovative exploration both at home and abroad. We hope to screen out safe, efficient and simple preparation methods and transplantation methods of iPSC-EVs through systematic experiments, establish an effective clinical evaluation system, and provide auxiliary means for intracranial and extracranial blood flow reconstruction surgery in the treatment of Moyamoya disease. Moreover, in terms of topic selection, iPSC is currently one of the most promising directions for innovative treatment worldwide.",[26],"2025-09-29",{"date":252,"type":31},"2025-10-01",{"date":254,"type":31},"2025-05-26",{"date":256,"type":20},"2026-10-31",{"name":258,"class":38},"Huaqiu Zhang",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":267,"targetDuration":149,"studyType":52,"phases":4,"briefSummary":269,"conditions":270,"keywords":613,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":665},"100193378","rare-disease-patient-registry--natural-history-study---coordination-of-rare-diseases-at-sanford-100193378","NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford","Coordination of Rare Diseases at Sanford","CoRDS","Inclusion Criteria:\n\n* Diagnosis of a rare disease, a disease of unknown prevalence, undiagnosed or an unaffected carrier of a rare\u002Funcommon disease\n\nExclusion Criteria:\n\n* Diagnosis of a disease which is not rare",{"count":268,"type":20},20000,"CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org\u002FCoRDS to enroll.",[271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,26,606,607,608,609,610,611,612],"Rare Disorders","Undiagnosed Disorders","Disorders of Unknown Prevalence","Cornelia De Lange Syndrome","Prenatal Benign Hypophosphatasia","Perinatal Lethal Hypophosphatasia","Odontohypophosphatasia","Adult Hypophosphatasia","Childhood-onset Hypophosphatasia","Infantile Hypophosphatasia","Hypophosphatasia","Kabuki Syndrome","Bohring-Opitz Syndrome","Narcolepsy Without Cataplexy","Narcolepsy-cataplexy","Hypersomnolence Disorder","Idiopathic Hypersomnia Without Long Sleep Time","Idiopathic Hypersomnia With Long Sleep Time","Idiopathic Hypersomnia","Kleine-Levin Syndrome","Kawasaki Disease","Leiomyosarcoma","Leiomyosarcoma of the Corpus Uteri","Leiomyosarcoma of the Cervix Uteri","Leiomyosarcoma of Small Intestine","Acquired Myasthenia Gravis","Addison Disease","Hyperacusis (Hyperacousis)","Juvenile Myasthenia Gravis","Transient Neonatal Myasthenia Gravis","Williams Syndrome","Lyme Disease","Myasthenia Gravis","Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)","Isolated Klippel-Feil Syndrome","Frasier Syndrome","Denys-Drash Syndrome","Beckwith-Wiedemann Syndrome","Emanuel Syndrome","Isolated Aniridia","Axenfeld-Rieger Syndrome","Aniridia-intellectual Disability Syndrome","Aniridia - Renal Agenesis - Psychomotor Retardation","Aniridia - Ptosis - Intellectual Disability - Familial Obesity","Aniridia - Cerebellar Ataxia - Intellectual Disability","Aniridia - Absent Patella","Aniridia","Peters Anomaly - Cataract","Peters Anomaly","Potocki-Shaffer Syndrome","Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11","Silver-Russell Syndrome Due to Imprinting Defect of 11p15","Silver-Russell Syndrome Due to 11p15 Microduplication","Syndromic Aniridia","WAGR Syndrome","Wolf-Hirschhorn Syndrome","4p16.3 Microduplication Syndrome","4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome","Autosomal Recessive Stickler Syndrome","Stickler Syndrome Type 2","Stickler Syndrome Type 1","Stickler Syndrome","Mucolipidosis Type 4","X-linked Spinocerebellar Ataxia Type 4","X-linked Spinocerebellar Ataxia Type 3","X-linked Intellectual Disability - Ataxia - Apraxia","X-linked Progressive Cerebellar Ataxia","X-linked Non Progressive Cerebellar Ataxia","X-linked Cerebellar Ataxia","Vitamin B12 Deficiency Ataxia","Toxic Exposure Ataxia","Unclassified Autosomal Dominant Spinocerebellar Ataxia","Thyroid Antibody Ataxia","Sporadic Adult-onset Ataxia of Unknown Etiology","Spinocerebellar Ataxia With Oculomotor Anomaly","Spinocerebellar Ataxia With Epilepsy","Spinocerebellar Ataxia With Axonal Neuropathy Type 2","Spinocerebellar Ataxia Type 8","Spinocerebellar Ataxia Type 7","Spinocerebellar Ataxia Type 6","Spinocerebellar Ataxia Type 5","Spinocerebellar Ataxia Type 4","Spinocerebellar Ataxia Type 37","Spinocerebellar Ataxia Type 36","Spinocerebellar Ataxia Type 35","Spinocerebellar Ataxia Type 34","Spinocerebellar Ataxia Type 32","Spinocerebellar Ataxia Type 31","Spinocerebellar Ataxia Type 30","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 29","Spinocerebellar Ataxia Type 28","Spinocerebellar Ataxia Type 27","Spinocerebellar Ataxia Type 26","Spinocerebellar Ataxia Type 25","Spinocerebellar Ataxia Type 23","Spinocerebellar Ataxia Type 22","Spinocerebellar Ataxia Type 21","Spinocerebellar Ataxia Type 20","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 19\u002F22","Spinocerebellar Ataxia Type 18","Spinocerebellar Ataxia Type 17","Spinocerebellar Ataxia Type 16","Spinocerebellar Ataxia Type 15\u002F16","Spinocerebellar Ataxia Type 14","Spinocerebellar Ataxia Type 13","Spinocerebellar Ataxia Type 12","Spinocerebellar Ataxia Type 11","Spinocerebellar Ataxia Type 10","Spinocerebellar Ataxia Type 1 With Axonal Neuropathy","Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia - Unknown","Spinocerebellar Ataxia - Dysmorphism","Non Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Spasticity-ataxia-gait Anomalies Syndrome","Spastic Ataxia With Congenital Miosis","Spastic Ataxia - Corneal Dystrophy","Spastic Ataxia","Rare Hereditary Ataxia","Rare Ataxia","Recessive Mitochondrial Ataxia Syndrome","Progressive Epilepsy and\u002For Ataxia With Myoclonus as a Major Feature","Posterior Column Ataxia - Retinitis Pigmentosa","Post-Stroke Ataxia","Post-Head Injury Ataxia","Post Vaccination Ataxia","Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract","Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus","Non-hereditary Degenerative Ataxia","Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity","Olivopontocerebellar Atrophy - Deafness","NARP Syndrome","Myoclonus - Cerebellar Ataxia - Deafness","Multiple System Atrophy, Parkinsonian Type","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy","Maternally-inherited Leigh Syndrome","Machado-Joseph Disease Type 3","Machado-Joseph Disease Type 2","Machado-Joseph Disease Type 1","Leigh Syndrome","Late-onset Ataxia With Dementia","Infection or Post Infection Ataxia","GAD Ataxia","Hereditary Episodic Ataxia","Gliadin\u002FGluten Ataxia","Friedreich Ataxia","Fragile X-associated Tremor\u002FAtaxia Syndrome","Familial Paroxysmal Ataxia","Exposure to Medications Ataxia","Episodic Ataxia With Slurred Speech","Episodic Ataxia Unknown Type","Episodic Ataxia Type 7","Episodic Ataxia Type 6","Episodic Ataxia Type 5","Episodic Ataxia Type 4","Episodic Ataxia Type 3","Episodic Ataxia Type 1","Epilepsy and\u002For Ataxia With Myoclonus as Major Feature","Early-onset Spastic Ataxia-neuropathy Syndrome","Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity","Early-onset Cerebellar Ataxia With Retained Tendon Reflexes","Early-onset Ataxia With Dementia","Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia","Dilated Cardiomyopathy With Ataxia","Cataract - Ataxia - Deafness","Cerebellar Ataxia, Cayman Type","Cerebellar Ataxia With Peripheral Neuropathy","Cerebellar Ataxia - Hypogonadism","Cerebellar Ataxia - Ectodermal Dysplasia","Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss","Brain Tumor Ataxia","Brachydactyly - Nystagmus - Cerebellar Ataxia","Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia","Autosomal Recessive Syndromic Cerebellar Ataxia","Autosomal Recessive Spastic Ataxia With Leukoencephalopathy","Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay","Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria","Autosomal Recessive Spastic Ataxia","Autosomal Recessive Metabolic Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine","Autosomal Recessive Ataxia, Beauce Type","Autosomal Recessive Ataxia Due to Ubiquinone Deficiency","Autosomal Recessive Ataxia Due to PEX10 Deficiency","Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia","Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency","Autosomal Recessive Congenital Cerebellar Ataxia","Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency","Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome","Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity","Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency","Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect","Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion","Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation","Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness","Autosomal Recessive Cerebellar Ataxia","Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly","Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation","Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy","Autosomal Dominant Spastic Ataxia Type 1","Autosomal Dominant Spastic Ataxia","Autosomal Dominant Optic Atrophy","Ataxia-telangiectasia Variant","Ataxia-telangiectasia","Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy","Autosomal Dominant Cerebellar Ataxia Type 4","Autosomal Dominant Cerebellar Ataxia Type 3","Autosomal Dominant Cerebellar Ataxia Type 2","Autosomal Dominant Cerebellar Ataxia Type 1","Autosomal Dominant Cerebellar Ataxia","Ataxia-telangiectasia-like Disorder","Ataxia With Vitamin E Deficiency","Ataxia With Dementia","Ataxia - Oculomotor Apraxia Type 1","Ataxia - Other","Ataxia - Genetic Diagnosis - Unknown","Acquired Ataxia","Adult-onset Autosomal Recessive Cerebellar Ataxia","Alcohol Related Ataxia","Multiple Endocrine Neoplasia","Multiple Endocrine Neoplasia Type II","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia, Type IV","Multiple Endocrine Neoplasia, Type 3","Multiple Endocrine Neoplasia (MEN) Syndrome","Multiple Endocrine Neoplasia Type 2B","Multiple Endocrine Neoplasia Type 2A","Atypical Hemolytic Uremic Syndrome","Atypical HUS","Wiedemann-Steiner Syndrome","Breast Implant-Associated Anaplastic Large Cell Lymphoma","Autoimmune\u002FInflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis","Behcet's Disease","Alagille Syndrome","Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)","Lowe Syndrome","Pitt Hopkins Syndrome","1p36 Deletion Syndrome","Jansen Type Metaphyseal Chondrodysplasia","Cockayne Syndrome","Chronic Recurrent Multifocal Osteomyelitis","CRMO","Malan Syndrome","Hereditary Sensory and Autonomic Neuropathy Type Ie","VCP Disease","Hypnic Jerking","Sleep Myoclonus","Mollaret Meningitis","Recurrent Viral Meningitis","CRB1","Leber Congenital Amaurosis","Retinitis Pigmentosa","Rare Retinal Disorder","KCNMA1-Channelopathy","Primary Biliary Cirrhosis","ZMYND11","Transient Global Amnesia","Glycogen Storage Disease","Alstrom Syndrome","White Sutton Syndrome","DNM1","EIEE31","Myhre Syndrome","Recurrent Respiratory Papillomatosis","Laryngeal Papillomatosis","Tracheal Papillomatosis","Refsum Disease","Nicolaides Baraitser Syndrome","Leukodystrophy","Tango2","Cauda Equina Syndrome","Rare Gastrointestinal Disorders","Achalasia-Addisonian Syndrome","Achalasia Cardia","Achalasia Icrocephaly Syndrome","Anal Fistula","Congenital Sucrase-Isomaltase Deficiency","Eosinophilic Gastroenteritis","Idiopathic Gastroparesis","Hirschsprung Disease","Rare Inflammatory Bowel Disease","Intestinal Pseudo-Obstruction","Scleroderma","Short Bowel Syndrome","Sacral Agenesis","Sacral Agenesis Syndrome","Caudal Regression","Scheuermann Disease","SMC1A Truncated Mutations (Causing Loss of Gene Function)","Cystinosis","Juvenile Nephropathic Cystinosis","Nephropathic Cystinosis","Kennedy Disease","Spinal Bulbar Muscular Atrophy","Warburg Micro Syndrome","Mucolipidoses","Mitochondrial Diseases","Mitochondrial Aminoacyl-tRNA Synthetases","Mt-aaRS Disorders","Hypertrophic Olivary Degeneration","Non-Ketotic Hyperglycinemia","Fish Odor Syndrome","Halitosis","Isolated Congenital Asplenia","Lambert Eaton (LEMS)","Biliary Atresia","STAG1 Gene Mutation","Coffin Lowry Syndrome","Borjeson-Forssman-Lehman Syndrome","Blau Syndrome","Arginase 1 Deficiency","HSPB8 Myopathy","Beta-Mannosidosis","TBX4 Syndrome","DHDDS Gene Mutations","MAND-MBD5-Associated Neurodevelopmental Disorder","Constitutional Mismatch Repair Deficiency (CMMRD)","SPATA5 Disorder","SPATA5L1 Related Disorder","Acrodysostosis","Multi-systematic Smooth Muscle Dysfunction Syndrome","CRELD1 (Cysteine Rich With EGF Like Domains 1)","GNB1 Syndrome","Pyruvate Dehydrogenase Complex Deficiency Disease","Beta Mannosidosis","Kbg Syndrome","Labrune Syndrome","Metachromatic Leukodystrophy (MLD)","OPHN1 Syndrome","Oculopharyngeal Muscular Dystrophy (OPMD)","TUBB3 Mutation","WOREE (WWOX-related Epileptic Encephalopathy","SCAR12","Skraban-Deardorff Syndrome","Hereditary Myopathy With Early Respiratory Failure",[614,615,616,617,618,325,619,620,332,621,291,622,623,624,495,504,625,626,282,627,628,290,629,292,630,281,631,632,507,633,634,510,511,635,513,514,636,637,517,638,639,640,567,641,642,643,644,645,646,647,572,648,649,650,577,578,651,652,653,654,655],"Rare Diseases","Neglected Diseases","Orphan Diseases","Rare Disease Research","Registries","Ataxia","Cornelia de Lange Syndrome","Ataxia Telangiectasia","Batten Disease","Mucolipidosis IV","Klippel-Feil Syndrome","Undiagnosed","Uncommon Disease","Hypersomnia","Hyperacusis","Marinesco-Sjogren Syndrome","4p-\u002FWolf-Hirschhorn Syndrome","Narcolepsy","Wiedermann-Steiner Syndrome","Autoimmune\u002Finflammatory Syndrome Induced by Adjuvants (ASIA)","Hemophagocytic Lymphohistiocytosis (HLH)","Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD)","1p36 deletion syndrome","Jansen metaphyseal chondrodysplasia","Chronic recurrent multifocal osteomyelitis (CRMO)","Malan syndrome","Hereditary Sensory and Autonomic Neuropathy","Juvenile nephropathic cystinosis","Nephropathic infantile cystinosis","Ocular cystinosis","Kennedy disease","Spinal Bulbar Muscular Atrophy (SBMA)","SMC1A Truncated Mutations (causing loss of gene function)","Leigh syndrome","Mucolipidosis","Mitochondrial aminoacyl-tRNA synthetases (Mt-aaRS Disorders)","Shine Syndrome","Intestinal Bromhidrosis Syndrome","Fish odor syndrome","Autosomal recessive extra oral halitosis","CACNA1H mutation","Dimethylglycine dehydrogenase deficiency","2025-05-22",{"date":658,"type":31},"2025-05-29",{"date":660,"type":31},"2010-07",{"date":662,"type":20},"2100-12",{"name":664,"class":38},"Sanford Health",2,{"id":667,"slug":668,"hasResults":11,"nctId":669,"briefTitle":670,"officialTitle":670,"acronym":4,"eligibilityCriteria":671,"healthyVolunteers":48,"sex":16,"minAge":77,"maxAge":672,"enrollmentInfo":673,"targetDuration":675,"studyType":52,"phases":4,"briefSummary":676,"conditions":677,"keywords":678,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":39},"100580095","study-on-the-mechanism-of-cognitive-impairment-in-patients-with-moyamoya-disease-100580095","NCT06832839","Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease","Inclusion Criteria:\n\n* The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease.\n* Please sign the informed consent form.\n* Participants must be between 18 and 60 years of age.\n\nExclusion Criteria:\n\n* Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome.\n* Individuals younger than 18 years or older than 60 years.\n* Those with contraindications for magnetic resonance imaging.\n* Patients who are unable to complete cognitive brain assessments","60 Years",{"count":674,"type":20},360,"24 Months","The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.",[26],[679,26],"Cognitive Impairment","2025-02-12",{"date":682,"type":31},"2025-02-18",{"date":684,"type":31},"2024-12-16",{"date":686,"type":20},"2027-12-31",{"name":69,"class":38},{"id":689,"slug":690,"hasResults":11,"nctId":691,"briefTitle":692,"officialTitle":693,"acronym":4,"eligibilityCriteria":694,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":695,"enrollmentInfo":696,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":698,"conditions":699,"keywords":700,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":704,"startDateStruct":706,"completionDateStruct":708,"leadSponsor":710,"locationsCount":39},"100519293","functional-magnetic-resonance-based-observations-of-brain-networks-in-moyamoya-disease-patients-under-anesthesia-100519293","NCT06041659","Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia","Functional Magnetic Resonance-Based Observations of Brain Networks and Cerebrovascular Reactivity in Patients With Moyamoya Disease Under Anesthetic Sedation, A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Patients with moyamoya disease scheduled for direct or indirect intracranial and extracranial revascularization surgery\n* Age between 18-65 years\n* Obtain written informed consent.\n\nExclusion Criteria:\n\n* Patients with preoperative claustrophobia, sensory or motor aphasia that are unable to understand and cooperate with the examination\n* Preoperative cranial imaging suggesting cerebral infarction lesion diameter \\>15mm\n* Patients allergic to anesthetic drugs\n* Metal implants in the body\n* Undergoing other experimental drug or instrumentation trials","65 Years",{"count":697,"type":20},48,"Moyamoya disease is characterized by progressive stenosis of the genesis of the distal internal carotid arteries bilaterally and progressive generation of compensatory pathological vascular networks at the basis cranii, and these pathological vasculature has poor vascular reactivity. Perioperative circulatory management of patients with smoky vessels to ensure perfusion of brain tissue and integrity of brain network during surgery to minimize postoperative impairment of neurological functions, including motor, sensory, emotional and cognitive functions, is the key point of perioperative circulatory management of moyamoya disease. Functional Magnetic Resonance Imaging (fMRI) has been routinely used in various cerebrovascular diseases to further evaluate cerebrovascular reserve and cerebral network connectivity. The purpose of this study is to observe the changes in cerebral blood flow, cerebral oxygen metabolism, cerebral oxygen metabolism rate, and cerebral network connectivity in adult patients with moyamoya disease in cerebral ischemia-sensitive areas under anesthesia to provide a basis for exploring anesthesia management to improve cognitive function and cerebral network connectivity in these patients.",[26],[26,701,702,703],"Cerebral Network","Cognitive Function","Anesthesia",{"date":705,"type":31},"2025-02-13",{"date":707,"type":31},"2023-10-24",{"date":709,"type":20},"2025-12-31",{"name":69,"class":38},{"id":712,"slug":713,"hasResults":11,"nctId":714,"briefTitle":715,"officialTitle":715,"acronym":716,"eligibilityCriteria":717,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":672,"enrollmentInfo":718,"targetDuration":720,"studyType":52,"phases":4,"briefSummary":721,"conditions":722,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":728,"leadSponsor":730,"locationsCount":39},"100578910","study-on-evaluating-the-effectiveness-of-statins-in-the-treatment-of-moyamoya-disease-100578910","NCT06817434","Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease","SEST-MOYA","Inclusion Criteria:\n\n1. The imaging examination meets the diagnostic criteria for moyamoya disease;\n2. Sign the informed consent form;\n3. Age ≥18 years old;\n4. Baseline mRS score ≤2 points;\n5. The patient receives revascularization\u002Fconservative treatment;\n6. There is at least 1 imaging follow-up result.\n\nExclusion Criteria:\n\n1. Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome;\n2. Individuals under the age of 18;\n3. Participants who refuse to take part in this study;\n4. Pregnant patients;\n5. Those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus;\n6. A history of stroke occurring more than three months prior to the diagnosis of Moyamoya disease;\n7. Individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation;\n8. Allergies to contrast media;\n9. Patients with missing imaging data or whose image quality cannot be analyzed;\n10. Individuals who refuse or are unable to undergo imaging follow-up;\n11. Patients receiving other types of lipid-lowering drug treatments.",{"count":719,"type":20},330,"18 Months","The purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.",[26],"2025-02-04",{"date":725,"type":31},"2025-02-10",{"date":727,"type":31},"2024-12-15",{"date":729,"type":20},"2026-12-31",{"name":69,"class":38},{"id":732,"slug":733,"hasResults":11,"nctId":734,"briefTitle":735,"officialTitle":736,"acronym":4,"eligibilityCriteria":737,"healthyVolunteers":11,"sex":16,"minAge":738,"maxAge":672,"enrollmentInfo":739,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":741,"conditions":742,"keywords":743,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":747,"startDateStruct":749,"completionDateStruct":751,"leadSponsor":752,"locationsCount":39},"100464827","long-term-outcomes-of-conservative-management-in-patients-with-moyamoya-disease-and-their-first-degree-relatives-lamora-100464827","NCT05332756","Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)","Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives","Inclusion Criteria:\n\n1. Patients with age between 2-60 years;\n2. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease.\n3. Patients are medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.\n4. Capable of understanding the purpose and risk of the study and has signed the informed consent. If the participant is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations.\n5. Ability to comply with study follow-up.\n\nExclusion Criteria:\n\n1. Concomitant other diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy.\n2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement.\n3. Patients are allergic to the contrast agents.\n4. Patients are treated with direct, indirect, or combined revascularization depending on the presentation.\n5. Physical or subjective failure to cooperate with the examination or serious comorbid diseases.\n6. Patients are unable or unlikely to return for follow-up visits.\n7. Any other reasons that, in the opinion of the investigators, make the participant unsuitable for enrollment.","2 Years",{"count":740,"type":20},400,"The purpose of this study is to investigate the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives, and provide potential pathogenesis of moyamoya disease.",[26],[26,744,745,746],"Conservative management","Long-term follow-up","First-degree relatives",{"date":748,"type":31},"2024-12-19",{"date":750,"type":31},"2022-05-01",{"date":729,"type":20},{"name":69,"class":38},{"id":754,"slug":755,"hasResults":11,"nctId":756,"briefTitle":757,"officialTitle":758,"acronym":759,"eligibilityCriteria":760,"healthyVolunteers":48,"sex":16,"minAge":77,"maxAge":177,"enrollmentInfo":761,"targetDuration":4,"studyType":21,"phases":763,"briefSummary":764,"conditions":765,"keywords":767,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":769,"lastUpdatePostDateStruct":770,"startDateStruct":772,"completionDateStruct":774,"leadSponsor":776,"locationsCount":39},"100541511","imaging-in-moyamoya-disease---study-to-investigate-different-imaging-technologies-for-a-better-understanding-of-various-imaging-techniques-to-evaluate-cerebral-hemodynamics-disease-activity-and-possibly-the-etiology-in-moyamoya-patients-100541511","NCT06330818","Imaging in Moyamoya Disease - Study to Investigate Different Imaging Technologies for a Better Understanding of Various Imaging Techniques to Evaluate Cerebral Hemodynamics, Disease-activity and Possibly the Etiology in Moyamoya Patients","IMAGINE - Imaging in Moyamoya Disease","IMAGINE","Inclusion Criteria:\n\n* Patients with suspicion of Moyamoya Disease\n* Patients able to understand the study and to give their informed consent\n\nExclusion Criteria:\n\n* Cerebral vascular disease caused by atherosclerosis\n* Vasculitis\n* Contraindications to MRI\n* Contraindications to PET\u002FCT\n* Pregnancy\n* Inability to give informed consent\n* Renal insufficiency",{"count":762,"type":20},50,[23],"Aim of this study is to improve patient care in Moyamoya Patients by improving Imaging technologies and aiming to identify factors involved in disease progression.\n\nMain tasks are:\n\n* Analysis of CO2-triggered BOLD fMRI for analysis of cerebral hemodynamics in comparison to H2 15O PET\u002FCT\n* Analysis of longitudinal changes of contrast enhancement in vessel-wall imaging and correlation of disease activity with biosampling\n* Definition of a standardized recommendation for pre- and postoperative imaging of Moyamoya patients",[26,766],"Moyamoya",[83,766,768],"EC-IC Bypass","2024-09-25",{"date":771,"type":31},"2024-09-26",{"date":773,"type":31},"2024-07-01",{"date":775,"type":20},"2027-11-30",{"name":777,"class":38},"University Hospital Tuebingen",{"id":779,"slug":780,"hasResults":11,"nctId":781,"briefTitle":782,"officialTitle":783,"acronym":784,"eligibilityCriteria":785,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":77,"enrollmentInfo":786,"targetDuration":4,"studyType":21,"phases":788,"briefSummary":789,"conditions":790,"keywords":792,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":796,"lastUpdatePostDateStruct":797,"startDateStruct":799,"completionDateStruct":801,"leadSponsor":803,"locationsCount":39},"100327682","safety-and-efficacy-of-ric-in-pediatric-moyamoya-disease-patients-treated-with-revascularization-therapy-100327682","NCT03546309","Safety and Efficacy of RIC in Pediatric Moyamoya Disease Patients Treated With Revascularization Therapy","Safety and Efficacy of Remote Ischemic Conditioning in Pediatric Moyamoya Disease Patients Treated With Revascularization Therapy","RIC-PMD","Inclusion Criteria:\n\n* Age: ≥0 and ≤18\n* All of the patients underwent digital subtraction angiography and met the current diagnostic criteria recommended by the Research Committee on MMD (Spontaneous Occlusion of the Circle of Willis) of the Ministry of Health and Welfare of Japan in 2012\n* Suzuki stages concentrated in Stage III and IV\n* Presentation with ischemic symptoms, such as transient ischemic attack (TIA), headache, seizure, hemorrhagic stroke, and ischemic stroke confirmed by MRI\n* Informed consent obtained from patient or acceptable patient's surrogate\n\nExclusion Criteria:\n\n* Severe hepatic or renal dysfunction\n* Severe hemostatic disorder or severe coagulation dysfunction\n* Patients with unilateral MMD or the presence of secondary moyamoya phenomenon caused by autoimmune disease, Down syndrome, neurofibromatosis, leptospiral infection, or previous skull-base radiation therapy\n* Any of the following cardiac disease - rheumatic mitral and or aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, patent foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis, or any other cardiovascular condition interfering with participation\n* Serious, advanced, or terminal illnesses with anticipated life expectancy of less than one year\n* Patient participating in a study involving other drug or device trial study\n* Patients with existing neurological or psychiatric disease that would confound the neurological or functional evaluations\n* Unlikely to be available for follow-up for 3 months\n* Contraindication for RIC - severe soft-tissue injury, fracture, or peripheral vascular disease in the upper limbs.",{"count":787,"type":20},42,[23],"Revascularization surgery has been the standard treatment to prevent ischemic stroke in pediatric Moyamoya disease (MMD) patients with ischemic symptoms. However, perioperative complications, such as hyperperfusion syndrome, new infarct on imaging, or ischemic stroke, are inevitable. Remote ischemic conditioning (RIC) is a noninvasive and easy-to-use neuroprotective strategy, and it has potential effects on preventing hyperperfusion syndrome and ischemic infarction.",[26,791],"Pediatric",[793,794,795],"pediatric moyamoya disease","remote ischemic conditioning","revascularization therapy","2024-09-12",{"date":798,"type":31},"2024-09-19",{"date":800,"type":20},"2024-09-10",{"date":802,"type":20},"2025-02-28",{"name":804,"class":38},"Capital Medical University",{"id":806,"slug":807,"hasResults":11,"nctId":808,"briefTitle":809,"officialTitle":810,"acronym":4,"eligibilityCriteria":811,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":812,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":814,"conditions":815,"keywords":816,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":820,"lastUpdatePostDateStruct":821,"startDateStruct":823,"completionDateStruct":825,"leadSponsor":827,"locationsCount":39},"100520053","prognostic-prediction-model-in-patients-with-moyamoya-disease-undergoing-revascularization-surgery-100520053","NCT06051552","Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery","Development and Validation for Muti-stage Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years.\n2. Imaging-confirmed moyamoya disease (CTA, CT angiography; MRA, magnetic resonance angiography；DSA, digital subtraction angiography）for MMD patients.\n3. Selective Revascularization Surgery (direct or indirect);\n4. Signed informed consent by the patient or legal representative.\n\nExclusion Criteria:\n\n1. patients with moyamoya syndrome due to an established secondary etiology.\n2. with severe cardiopulmonary disease that, in the opinion of the investigator, makes them unsuitable for participation in this study.\n3. patients with a life expectancy of less than 3 months or otherwise unable to complete this study.\n4. contraindication to DSA examination, severe contrast allergy or absolute contraindication to iodine contrast;\n5. women of childbearing age who have a negative pregnancy test but refuse to use effective contraception.\n6. women during pregnancy or breastfeeding.\n7. those who are unable to complete the study due to psychiatric disorders, cognitive or mood disorders.\n8. other patients who, in the opinion of the investigator, are not suitable for enrollment in the study (indicate reason).",{"count":813,"type":20},350,"Moyamoya Disease (MMD) is a rare chronic cerebrovascular disease characterized by progressive occlusion of the internal carotid artery or its major branches, with blood flow compensated by the formation of an abnormal vascular network (smoky). According to the latest national epidemiological survey in 2022, the cumulative number of new cases in the population was 47,443 in two years, with the annual incidence rate increasing year by year. The first symptoms are mainly cerebral infarction, transient ischemic attack, intracranial hemorrhage, and epileptic seizure, and the onset of the disease is concentrated in the age group of 45-54 years old, which is one of the most important causes of new strokes in middle-aged and young people and imposes a heavy medical burden on the society and the family. As one of the major causes of new strokes in young and middle-aged people, it brings a heavy medical burden to society and families. Hemodialysis has been confirmed as a standard treatment for patients with smokers' disease in large sample studies to prevent bleeding and recurrence of hemorrhage; however, there is no better consensus on which anesthetic technique to use for hemodialysis in patients with MMD. Currently, the more perfect prediction model is the postoperative collateral compensation formation prediction model for direct and indirect hemodialysis, which has the advantage of making full use of the patients' preoperative baseline variables and imaging characteristics, but the relatively insufficient inclusion of the sample size and the lack of intraoperative (vital signs, respiratory parameters, local cerebral oxygenation, etc.) and postoperative (postoperative neurological injury markers, etc.) variables included in the model limits the clinical scenarios. The lack of intraoperative (vital signs, respiratory parameters, local cerebral oxygen saturation) and postoperative (postoperative neurologic injury markers) variables limits the clinical application scenarios and is unable to guide the clinical decision-making and prognosis in the important stages of the perioperative period. This study aims to establish a prospective cohort database for MMD hemodialysis that includes perioperative anesthesia management, intraoperative treatment data, and postoperative treatment variables; to integrate preoperative, intraoperative, postoperative, and near- and long-term prognostic data from multiple sources, and to construct a perioperative multi-stage, multi-dimensional prognostic prediction model.",[26],[817,26,818,819,703],"Perioperative management","Predictive Model","Revascularization Surgery","2023-09-18",{"date":822,"type":31},"2023-09-25",{"date":824,"type":20},"2023-10-01",{"date":826,"type":20},"2026-09-30",{"name":69,"class":38},{"id":829,"slug":830,"hasResults":11,"nctId":831,"briefTitle":832,"officialTitle":832,"acronym":833,"eligibilityCriteria":834,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":835,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":837,"conditions":838,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":850,"lastUpdatePostDateStruct":851,"startDateStruct":853,"completionDateStruct":855,"leadSponsor":857,"locationsCount":858},"100513152","registry-of-multicenter-brain-heart-comorbidity-in-china-100513152","NCT05961748","Registry of Multicenter Brain-Heart Comorbidity in China","BHC-C","Inclusion Criteria:\n\n* age \\> 18 years old\n* Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \\[i.e., ACS\\], I46 (cardiac arrest), I48 (Atrial fibrillation\u002Fflutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).\n\nExclusion Criteria:\n\n·refuse to participate in the registry",{"count":836,"type":20},100000,"This study is a multi-center, prospective, registry study. This research was supported by the National Key Research and Development Program. To establish a domestic multi-center, large-scale \"brain-heart comorbidity\" dynamic database platform including clinical, sample database, image and other multi-dimensional information requirements, through the construction of a multi-center intelligent scientific research integration platform based on artificial intelligence.\n\nAny of newly diagnosed cardiovascular related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \\[i.e., ACS\\], I46 (cardiac arrest), I48 (Atrial fibrillation\u002Fflutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).\n\nThe data is stored on the brain-heart comorbidity warehouse via a physical server at the institution's data centre or a virtual hosted appliance. The brain-heart comorbidity platform comprises of a series of these appliances connected into a multicenter network. This network can broadcast queries to each appliance. Results are subsequently collected and aggregated. Once the data is sent to the network, it is mapped to a standard and controlled set of clinical terminologies and undergoes a data quality assessment including 'data cleaning' that rejects records which do not meet the brain-heart comorbidity quality standards. The brain-heart comorbidity warehouse performs internal and extensive data quality assessment with every refresh based on conformance, completeness, and plausibility (http:\u002F\u002F10.100.101.65:30080\u002Flogin).",[839,840,841,842,843,117,844,845,846,847,848,26,849],"Ischemic Heart Disease","Cardiac Arrest","Atrial Fibrillation","Heart Failure","Aortic Diseases","Intracerebral Hemorrhage","Cerebral Infarction","Occlusion and Stenosis of Precerebral Arteries","Occlusion and Stenosis of Cerebellar Arteries","Cerebral Aneurysm","Arteriovenous Malformation of Cerebral Vessels","2023-09-16",{"date":852,"type":31},"2023-09-21",{"date":854,"type":31},"2012-01-01",{"date":856,"type":20},"2032-12-31",{"name":69,"class":38},14,{"id":860,"slug":861,"hasResults":11,"nctId":862,"briefTitle":863,"officialTitle":864,"acronym":4,"eligibilityCriteria":865,"healthyVolunteers":11,"sex":16,"minAge":866,"maxAge":672,"enrollmentInfo":867,"targetDuration":869,"studyType":52,"phases":4,"briefSummary":870,"conditions":871,"keywords":874,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":878,"lastUpdatePostDateStruct":879,"startDateStruct":881,"completionDateStruct":883,"leadSponsor":884,"locationsCount":39},"100486822","the-evolution-and-prognosis-of-moyamoya-disease-100486822","NCT05619068","The Evolution and Prognosis of Moyamoya Disease","Imaging Investigation on the Evolution and Prognosis of Moyamoya Disease","Inclusion Criteria:\n\n* Patients with MMD: Conventional angiography or MRI examination conforms to the Guidelines for Diagnosis and Treatment of MMD (Neurol Med Chir (Tokyo) 52, 245-266, 2012), It is characterized by stenosis or occlusion of the end of the internal carotid artery, anterior cerebral artery and\u002For the beginning of the middle cerebral artery of unknown cause, accompanied by dilatation of the perforating artery at the base of the brain or of capillaries on the surface of the brain, i.e., the formation of smoke vessels. Sign the informed consent. Older than 10 and younger than 60. The education level of patients reached primary school or above (years of education ≥6).\n\nExclusion Criteria:\n\n* Patients with massive cerebral infarction, multiple paraventricular ischemic foci, or significantly enlarged ventricular hydrocephalus after intracerebral hemorrhage. Patients with vascular diseases caused by immune system disease. Patients can not cooperate to complete the cognitive function test. There are other neuropsychiatric diseases that affect cognitive function (such as Alzheimer's disease, Parkinson's disease, depression, anxiety disorder, cerebral hemorrhage, hydrocephalus, craniocerebral trauma, etc.). Patients with contraindications of magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies) or unable to complete image collection.","10 Years",{"count":868,"type":20},300,"5 Years","To investigate the evolution of imaging appearances and cognitive function of Moyamoya disease (MMD) and to establish a prognosis evaluation system based on imaging biomarkers in MMD. The study may be helpful to optimize and improve the diagnosis and pretreatment assessment of MMD, and provide an important theoretical supplement to the existing guidelines for the management of MMD.",[26,872,679,873],"Revascularization","Functional Impairment",[875,872,876,877],"Moyamoya disease","Cognitive impairment","Functional impairment","2022-12-19",{"date":880,"type":31},"2022-12-21",{"date":882,"type":31},"2022-09-01",{"date":686,"type":20},{"name":885,"class":38},"Chinese PLA General Hospital"]